Q2 EPS Estimates for Nuvation Bio Lowered by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Analysts at HC Wainwright dropped their Q2 2026 EPS estimates for Nuvation Bio in a report issued on Tuesday, May 5th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.14) for the quarter, down from their prior estimate of ($0.12). HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q3 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.33) EPS.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings data on Monday, May 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. The firm had revenue of $83.23 million for the quarter, compared to the consensus estimate of $66.22 million.

A number of other equities research analysts have also recently commented on NUVB. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research report on Tuesday, April 21st. Royal Bank Of Canada reissued an “outperform” rating and set a $20.00 target price on shares of Nuvation Bio in a research report on Tuesday. UBS Group decreased their target price on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, March 3rd. Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Nuvation Bio in a research report on Tuesday. Finally, Truist Financial set a $13.00 target price on shares of Nuvation Bio in a research report on Tuesday, January 27th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Nuvation Bio presently has an average rating of “Moderate Buy” and an average price target of $12.50.

Nuvation Bio Price Performance

NYSE NUVB opened at $5.04 on Thursday. Nuvation Bio has a 52-week low of $1.57 and a 52-week high of $9.75. The firm’s 50 day moving average price is $4.70 and its 200-day moving average price is $5.94. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.81 and a current ratio of 7.44. The company has a market cap of $1.75 billion, a PE ratio of -11.73 and a beta of 1.51.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC raised its holdings in shares of Nuvation Bio by 121.1% in the first quarter. Sanctuary Advisors LLC now owns 33,508 shares of the company’s stock worth $144,000 after buying an additional 18,351 shares during the last quarter. Kornitzer Capital Management Inc. KS purchased a new position in shares of Nuvation Bio in the first quarter worth $634,000. Hsbc Holdings PLC purchased a new position in shares of Nuvation Bio in the first quarter worth $101,000. Revisor Wealth Management LLC raised its holdings in shares of Nuvation Bio by 40.3% in the first quarter. Revisor Wealth Management LLC now owns 18,520 shares of the company’s stock worth $79,000 after buying an additional 5,317 shares during the last quarter. Finally, AMI Asset Management Corp raised its holdings in shares of Nuvation Bio by 52.1% in the first quarter. AMI Asset Management Corp now owns 192,427 shares of the company’s stock worth $826,000 after buying an additional 65,955 shares during the last quarter. Hedge funds and other institutional investors own 61.67% of the company’s stock.

Insiders Place Their Bets

In other Nuvation Bio news, insider Dongfang Liu sold 50,000 shares of the firm’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $5.02, for a total value of $251,000.00. Following the completion of the transaction, the insider owned 18,000 shares of the company’s stock, valued at approximately $90,360. This trade represents a 73.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kerry Wentworth sold 200,000 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $4.52, for a total transaction of $904,000.00. Following the completion of the transaction, the insider directly owned 53,000 shares of the company’s stock, valued at approximately $239,560. This represents a 79.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 286,750 shares of company stock valued at $1,339,118. Corporate insiders own 30.11% of the company’s stock.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.